Please try another search
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Name | Age | Since | Title |
---|---|---|---|
Alon Seri-Levy | 60 | 1997 | Co-Founder, CEO & Director |
Moshe Arkin | 70 | 2014 | Executive Chairman of the Board |
Ran Gottfried | 79 | 2018 | Lead Independent Director |
Itai Arkin | 36 | 2018 | Director |
Hanna Lerman | 51 | 2018 | Director |
Jonathan B. Siegel | 50 | 2018 | Independent Director |
Sharon Kochan | 55 | 2023 | Director |
Yuval Yanai | 71 | 2024 | Independent External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review